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Abstract
Coronavirus disease-19 (COVID-19) is a pandemic viral disease that can cause devastating complications such as 
acute respiratory disease, especially in patients with comorbidities. We do not know yet full pictures of this disease, 
especially in hematological malignancies. Here, we present management of a 57-year-old male with chronic phase 
chronic myeloid leukemia, tested positive for COVID-19, then complicated with acute respiratory distress syndrome.
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Introduction
Chronic myelogenous leukemia (CML) is a 
myeloproliferative disorder characterized by increased 
proliferation of the granulocytic cell line without the loss 
of their capacity to differentiate. The peripheral blood 
shows an increased number of granulocytes and their 
immature precursors, including occasional blast cells.
CML is caused by a single, specific genetic 
mutation, known as the Philadelphia chromosome. 
CML progresses through three phases: Chronic, 
accelerated, and blast. CML accounts for 20% of all 
leukemia affecting adults. Historically, the median 
survival of patients with CML was 3–5 years from the 
time of diagnosis. At present, patients with CML have a 
median survival of 5 or more years. In fact, CML patients 
are currently approaching normal life expectancy.as a 
result of the improvement of earlier diagnosis, improved 
therapy with target therapy, tyrosine kinase inhibitors 
(TKI).
The coronavirus pandemic, is an ongoing 
pandemic of coronavirus disease 2019 (COVID-
19), caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). The outbreak was first 
identified in Wuhan, China, in December 2019. Cases 
presentation ranged from mild asymptomatic cases up 
to sever pneumonia, cytokine storm syndrome, and 
ARDS.
There are no available specific data on the 
COVID-19 in CML patients treated with (TKI).
At present, we have no evidence to suggest 
that chronic phase CML patients on TKI are at higher 
risk of contracting SARS-CoV-2 or having a more 
severe form of the viral infection compared to the 
general population.
In this case report, we will present how we 
managed a case of CML that presented with sever 
COVID 19 infection.
Case Presentation
A 57-year-old male patient with history of 
diabetes mellitus (DM) on metformin 850 mg twice daily, 
diagnosed as chronic phase CML 10 years ago and he 
was started and maintained on imatinib 400 mg OD and 
achieved major molecular response (MMR). Last PCR 
for BCR-ABL 3 months ago 0.0001%.
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He presented to Emergency Department (ED) 
May 19, 2020, in King Salman Specialist Hospital, Hail, 
Kingdom of Saudi Arabia, complaining of cough for 2 
days, with fever, nausea no shortness of breath, no 
abdominal pain no vomiting, no diarrhea, no history of 
contact with positive case of COVID 19. On examination: 
He looks well, conscious, temperature was 38.4°C, 
other vital data within normal, chest examination was 
normal, abdomen: Soft and lax. White blood cell 5.75 
× 106/µL absolute neutrophil count (ANC) 4.37 × 106/µL 
lymphocytes 1.1 × 106/µL hemoglobin 14.6 g/dL platelet 
220 × 109/L, normal kidney and liver function tests, 
blood sugar 12 mmol, and normal chest X-ray (CXR).
COVID 19 swab taken and patient received 
paracetamol and antitussive, his medications of DM 
are modified, and advised for home isolation and to 
continue on imatinib 400 mg.
Two days later he returned to ED with complain 
of epigastric burning sensation, associated with loss of 
appetite, diarrhea for 1 day and productive cough.
Temperature was 37.5°C, heart rate was 
103/min, oxygen saturation (O2 Sat) 89% on room air, 
BP 160/90, chest examination: Equal bilateral air entry, 
and no adventitious sounds (Table 1).
He was admitted in isolation ward and he 
was started on hydroxyclorouquine, azithromycin, 
ceftriaxone, and prophylactic enoxaparin as per 
protocol. With ECG monitor of QT interval, and he 
continued on imatinib 400 mg OD.
On 2nd day of admission patient developed 
dyspnea his temperature increased to 39°C, O2 sat 
88% on 5 L/min nasal cannula. Chest exam showed 
bilateral crepitations, CXR: Bilateral infiltrations.
Patient shifted to ICU for close monitoring 
and we continued on imatinib 400 mg daily as no drug 
interaction with his medications and normal ANC, 
platelet, and liver function tests (Table 2, Figure 1).
Patient stayed in ICU for 2 days with stable 
condition, but with fluctuation of temperature, and O2 Sat.
On 3rd day of ICU admission, his O2 Sat 
markedly deteriorated.
Patient was sedated, intubated and kept on 
mechanical ventilation AC (MODE) VT, 440. RR, 20. 
PEEP, 10. FIO2, 50%.
Figure 1: Chest X-ray of patient on day of admission to ICU
We started patient on following medications 
based on local COVID-19 management protocol: 
Therapeutic dose of anticoagulation of enoxaparin 
1 mg /kg/BID SC, as D-DIMER more than 1 and he has 
severe COVID 19 pneumonia.
Methylprednisolone 40 mg IV q12h, 
lopinavir/ritonavir 400/100 mg q12h oral for 14 days, 
ribavirin 400 mg q12 h oral for 14 days, interferon Beta 
1-b 8MIU SC every other day for 3 doses.
4 h later he developed metabolic acidosis as 
he developed DKA that was appropriately managed.
We kept him on mechanical ventilation for 
5 days, he was stable, afebrile, maintained normal 
O2 Sat, and normal vital data. With regular laboratory 
follow-up, especially D-dimer and lymphocytes count 
(Figures 2 and 3) We kept imatinib on hold during days 
of intubation and mechanical ventilation.
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Figure 2: Lymphocytes count during course of the disease
After extubating him, as patient is clinically 
stable, we resumed imatinib. However, as patient is 
receiving ritonavir which has interaction with imatinib 
leading to increasing effect of imatinib, we reduced 
dose of imatinib by 50%, 200 mg OD till he finished 
antiviral therapy.
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Figure 3: D-dimer level during course of the disease
Patient finished 14 days of antiviral, his PCR for 
COVID 19 come negative twice, we resumed imatinib 
400 mg daily and discharged patient on prophylactic 
dose of enoxaparin 6000 IU for 45 days, we could not 
start direct oral anticoagulant due to its interaction with 
imatinib as both potentiate toxicity of each other. Twenty 
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days later Q-PCR for BCR-ABL is repeated and confirm 
patient still in MMR.
Discussion
SARS-CoV-2 is a zoonotic beta-coronavirus, 
similar to Middle East respiratory syndrome (MERS) 
and SARS-CoV-1, which causes a respiratory illness 
known as COVID-19. Most cases have mild symptoms, 
for example, fever, exhaustion, and dry cough [1]. 
Notwithstanding, a few cases are serious and may be 
confounded by ARDS prompting mechanical ventilation. 
The infection could be serious and complications are 
frequently found among patients with comorbidities, 
such as hypertension and respiratory and cardiovascular 
system diseases [2].
Some studies have suggested that cancer 
patients are more vulnerable to infection with SARS-
CoV-2 than healthy people and have a worse prognosis 
because their immune systems are suppressed by the 
effects of the tumors and anti-cancer treatment [3]. 
However, this view is controversial [4].
CML is a neoplastic disease of hematopoietic 
stem cells that have an annual incidence of 0.4–
1.75/100,000 11–15, the therapeutic landscape of 
chronic myeloid leukemia (CML) has significantly 
changed over the previous year. Most patients with 
chronic phase (CP) now have a normal life expectancy. 
Our goal is achieving a stable deep molecular response 
(DMR) and discontinuing medication for treatment-free 
remission (TFR). TKIs have improved patient outcomes 
to near-normal, and thereby survival. Imatinib was 
the first generation TKI that showed higher rates of 
cytogenetic and molecular responses [5].
There is no proof that hematological 
neoplasms, for example, CML, regardless of whether 
they are on TKIs, may put the patient at high hazard for 
COVID-19 and its complications [6].
In one study done in Wuhan, they studied 
SARS-CoV-2 infections in CML patients according to 
their response to anti-CML therapy, and found that just 
1 of 299 (0.3%) patients with an optimal response was 
diagnosed with COVID-19. Of the 50 patients who failed 
to respond to CML treatment or had a poor response, 
1 patient (2%) had a clinical diagnosis of COVID-
19. Thus, patients who failed to achieved an optimal 
response to CML therapy appear more likely to have a 
symptomatic infection with SARS-CoV-2 [7]. This may 
be explained by; an optimal response to TKI treatment 
may be associated with immune recovery. CML patients 
exhibit selective depletion of effector T-reg cells [8], [9], 
while TKIs increase the number of natural killer cells 
(NK), NK-LGL, and T-LGLs cells [10], which play a role 
in regulating immunity. Moreover, the previous studies 
have reported that imatinib and other TKI drugs have 
antiviral activity in vitro against MERS-COV and SARS-
COV [11], although the risk of infection in patients with 
CML on dasatinib is debatable [6].
Table 1: Laboratory test results on the day of admission
Laboratory test Value Normal range
White blood cell 8.18×106/µL 4–10
Absolute neutrophil count 6.34×106/µL 2–7
Lymphocytes count 1×106/µL 1.5–3
Hemoglobin 13.9 g/dL 13–17
Platelet 240×109/L 150–400
Ferritin 1594 ng/mL 22–322
LDH 419 U/L 125–135
D-dimer 1.79 mg/L 0.00–0.49
LDH: Lactate dehydrogenase.
In case presented here, our patient had optimal 
response to imatinib, so we did not stop imatinib during 
course of the disease based on the previous data 
but after intubation and mechanical ventilation, his 
prognosis was dismal, and we do not have enough data 
about continuation of CML therapy at that time, so we 
hold it.
Table 2: Laboratory tests on date of ICU admission
Laboratory test Value Normal range
WBC 6×106/µL 4–10
Absolute neutrophil count 4.57×106/µL 2–7
Lymphocytes count 0.45×106/µL 1.5–3
Hemoglobin 12.5 g/dL 13–17
Platelet 454×109/L 150–400
Ferritin 1650 ng/mL 22–322
LDH 600 U/L 125–135
D-dimer 7.9 mg/L 0.00–0.49
LDH: Lactate dehydrogenase.
There is a variable risk of infectious 
complications with targeted therapy. According to 
Reinwald et al., kinase inhibitors that target the mTOR, 
Janus kinase and BCR pathways exhibit an increased 
risk of infection, sometimes fatal complications; 
while this risk is minor with kinase inhibitors of the 
angiogenesis-related growth factors [12].
Interestingly, analysis of virus-host interaction 
retrieved available anti-cancer target therapy that can 
potentially act against the SARS-CoV-2, among these 
drugs, a TKI (afatinib) and a proteasome inhibitor 
(ixazomib) [13]. Furthermore, the previous studies have 
highlighted the use of kinase inhibitors in the reduction 
of virus infectivity and this led some researchers to 
investigate the role of anti-tyrosine kinase such as 
sunitinib and erlotinib in the treatment of COVID-19 [14].
Our patient responded as all other patient 
with profound lymphopenia and high D-dimer when he 
developed sever COVID 19 pneumonia and ARDS.
Lymphopenia is the most common laboratory 
finding. However, leukocytosis and leukopenia have 
been reported [15]. Lymphocyte count and lymphopenia 
may serve as a rapid tool that can quickly identify COVID-
19 patients with more severe clinical presentation, viral 
infection may either directly suppress bone marrow or 
induce an immune-mediated destruction of lymphocytes 
resulting in lymphopenia [16], [17]. Thrombocytopenia 
is more common in patients with critical diseases, 
and it could also distinguish between mild and severe 
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cases [18]. Some patients might develop cytokine storm 
or secondary hemophagocytic lymphohistiocytosis, 
which is characterized mainly by cytopenias and 
hyperferritinemia plus the other features [19].
Infection with the novel coronavirus SARS-
CoV-2 has been associated with inflammation and a 
hypercoagulable state, with increases in fibrin, fibrin 
degradation products, fibrinogen, and D-dimers and 
it associated worse clinical outcomes [20]. There is a 
potential role for coagulopathy in COVID-19. Although 
the exact mechanism may remain controversial, it is not 
typical of disseminated intravascular coagulopathy of 
the kind seen in septicemia [21].
Heparin has been implicated in binding to 
COVID-19 spike proteins as well as down-regulating 
interleukin-6 (IL-6) [22], which has been shown to be 
elevated in COVID-19 patients, and thus unfractioned 
heparin or LMWH remains as the best choice of 
anticoagulant for those patients. It is possible that these 
patients may even require continued anticoagulation for 
a certain period of time following hospital discharge [21] 
and we followed this statement in our patient.
Finally, good responders to TKIs in CML are 
less likely to develop symptoms of SARS-CoV-2 than 
non-responders [7]. Hence, clinicians are encouraged 
not to withhold targeted therapy for good responders 
rather than pursuing it where not indicated; and this 
principle is also true irrespective of the pandemic.
Conclusion
In the presence of non-severe confirmed SARS-
CoV-2, interruption of TKI treatment is not necessary. In 
case of severe SARS-CoV-2, TKI interruption should be 
discussed on a case-to case basis.
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